The stock of Edwards Lifesciences Corp (EW) has seen a 2.56% increase in the past week, with a 3.04% gain in the past month, and a -21.84% decrease in the past quarter. The volatility ratio for the week is 3.11%, and the volatility levels for the past 30 days are at 2.86% for EW. The simple moving average for the past 20 days is -0.25% for EW’s stock, with a -15.85% simple moving average for the past 200 days.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio that is above its average at 28.20x. The stock has a 36-month beta value of 1.13. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 7 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EW is 592.02M, and at present, short sellers hold a 1.06% of that float. On September 16, 2024, the average trading volume of EW was 5.63M shares.
EW) stock’s latest price update
The stock of Edwards Lifesciences Corp (NYSE: EW) has increased by 0.57 when compared to last closing price of 68.13. Despite this, the company has experienced a 2.56% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-09-13 that NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation (“Edwards Lifesciences”) (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
Analysts’ Opinion of EW
Truist gave a rating of “Hold” to EW, setting the target price at $82 in the report published on July 25th of the current year.
EW Trading at -6.50% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.71% of loss for the given period.
Volatility was left at 2.86%, however, over the last 30 days, the volatility rate increased by 3.11%, as shares surge +0.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.77% lower at present.
During the last 5 trading sessions, EW rose by +2.56%, which changed the moving average for the period of 200-days by +2.03% in comparison to the 20-day moving average, which settled at $68.71. In addition, Edwards Lifesciences Corp saw -10.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from BOBO DONALD E JR, who sale 5,000 shares at the price of $66.77 back on Sep 11 ’24. After this action, BOBO DONALD E JR now owns 46,936 shares of Edwards Lifesciences Corp, valued at $333,826 using the latest closing price.
Chopra Daveen, the CVP, TMTT of Edwards Lifesciences Corp, sale 1,250 shares at $69.95 during a trade that took place back on Aug 20 ’24, which means that Chopra Daveen is holding 29,333 shares at $87,438 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.25. The total capital return value is set at 0.18. Equity return is now at value 21.35, with 15.44 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 58.31.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 6.72. The receivables turnover for the company is 7.19for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
To sum up, Edwards Lifesciences Corp (EW) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
